ABSTRACT
<p><b>OBJECTIVE</b>To express and purify H5N1 influenza virus (A/Anhui/1/2005) NP in prokaryotic system and to explore the NP-interacting proteins of human bronchial epithelial cells BEAS-2B in vitro.</p><p><b>METHODS</b>The full length H5N1 NP gene fragment was amplified by PCR, inserted into prokaryotic expression vector (pET30a) to generate NP expression plasmid pET30a-NP. After transforming pET30a-NP into E. coli (BL21), the expression of soluble NP protein was induced by IPTG. The expressed NP protein was purified by two steps with metal chelation chromatography and ion exchange chromatography. Then the total proteins of BEAS-2B cells was extracted for screening the components which have protein-protein interaction with purified NP by pull-down and LC-MS/MS methods.</p><p><b>RESULTS</b>The expression of H5N1 NP protein could be induced by IPTG in bacterial system using expression plasmid pET30a-NP. The soluble NP was purified. Twenty proteins were found by pull-down and LC-MS/MS, the further experiments may be needed to prove protein-protein interaction between them.</p><p><b>CONCLUSION</b>The soluble H5N1 NP fusion protein with high purity was obtained and twenty proteins were found which could interact with it by pull-down and LC-MS/MS.</p>
Subject(s)
Humans , Cell Line , Influenza A Virus, H5N1 Subtype , Genetics , Metabolism , Influenza, Human , Metabolism , Virology , Protein Binding , RNA-Binding Proteins , Genetics , Metabolism , Recombinant Proteins , Genetics , Metabolism , Viral Core Proteins , Genetics , MetabolismABSTRACT
<p><b>OBJECTIVE</b>To construct adenovirus vector vaccine against H5N1 influenza virus and study on the immunogenicity.</p><p><b>METHODS</b>In this study, we amplified hemagglutinin (HA) gene sequence of H5N1 influenza virus (A/Anhui/1/2005), then constructed an adenovirus vector vaccine (Adv-HA), followed by tests in BALB/c mice for the immunogenicity with the vaccine and immunization strategies.</p><p><b>RESULTS</b>The recombinate Adv-HA vaccine could effectively induce both humoral and cellular immunity against human H5N1 influenza virus.</p><p><b>CONCLUSION</b>The Adv-HA vaccination against H5N1 influenza is a potential strategy and worthy of further investigation.</p>